Creative Financial Designs Inc. ADV Cuts Holdings in DaVita Inc. (NYSE:DVA)

Creative Financial Designs Inc. ADV trimmed its holdings in shares of DaVita Inc. (NYSE:DVA) by 23.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,063 shares of the company’s stock after selling 318 shares during the period. Creative Financial Designs Inc. ADV’s holdings in DaVita were worth $159,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of DVA. Amundi raised its stake in shares of DaVita by 116.4% during the 4th quarter. Amundi now owns 446,386 shares of the company’s stock worth $68,726,000 after buying an additional 240,126 shares in the last quarter. FMR LLC raised its stake in shares of DaVita by 659.9% during the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after buying an additional 154,061 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in shares of DaVita by 256.8% during the 4th quarter. Skandinaviska Enskilda Banken AB publ now owns 162,233 shares of the company’s stock worth $24,301,000 after buying an additional 116,758 shares in the last quarter. Glenmede Trust Co. NA raised its stake in shares of DaVita by 731.6% during the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after buying an additional 108,446 shares in the last quarter. Finally, JPMorgan Chase & Co. increased its stake in DaVita by 17.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock valued at $99,846,000 after purchasing an additional 92,014 shares in the last quarter. 90.12% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Barclays raised their price objective on DaVita from $164.00 to $169.00 and gave the company an “equal weight” rating in a research note on Tuesday, February 18th. Cowen reaffirmed a “hold” rating on shares of DaVita in a research note on Tuesday, February 18th. Finally, Sanford C. Bernstein set a $184.00 price objective on DaVita in a research note on Friday, February 21st. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat.com, DaVita presently has a consensus rating of “Hold” and an average target price of $166.33.

DaVita Price Performance

Shares of NYSE:DVA opened at $150.00 on Thursday. The business’s fifty day moving average price is $158.73 and its two-hundred day moving average price is $157.55. The stock has a market cap of $12.00 billion, a PE ratio of 13.97, a price-to-earnings-growth ratio of 1.07 and a beta of 0.99. The company has a debt-to-equity ratio of 23.18, a quick ratio of 1.21 and a current ratio of 1.26. DaVita Inc. has a one year low of $125.64 and a one year high of $179.60.

DaVita (NYSE:DVA) last announced its earnings results on Thursday, February 13th. The company reported $2.24 EPS for the quarter, beating analysts’ consensus estimates of $2.14 by $0.10. DaVita had a return on equity of 115.48% and a net margin of 7.31%. On average, analysts forecast that DaVita Inc. will post 10.76 EPS for the current fiscal year.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.